Cargando…
Development of Novel Arginase Inhibitors for Therapy of Endothelial Dysfunction
Endothelial dysfunction and resulting vascular pathology have been identified as an early hallmark of multiple diseases, including diabetes mellitus. One of the major contributors to endothelial dysfunction is a decrease in nitric oxide (NO) bioavailability, impaired NO signaling, and an increase in...
Autores principales: | Steppan, Jochen, Nyhan, Daniel, Berkowitz, Dan E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774993/ https://www.ncbi.nlm.nih.gov/pubmed/24062745 http://dx.doi.org/10.3389/fimmu.2013.00278 |
Ejemplares similares
-
Endothelial arginase II and atherosclerosis
por: Ryoo, Sungwoo, et al.
Publicado: (2011) -
Arginase Promotes Skeletal Muscle Arteriolar Endothelial Dysfunction in Diabetic Rats
por: Johnson, Fruzsina K., et al.
Publicado: (2013) -
Vascular Stiffness and Increased Pulse Pressure in the Aging Cardiovascular System
por: Steppan, Jochen, et al.
Publicado: (2011) -
Arginase Inhibitor in the Pharmacological Correction of Endothelial Dysfunction
por: Pokrovskiy, Mihail V., et al.
Publicado: (2011) -
Increased arginase II activity contributes to endothelial dysfunction through endothelial nitric oxide synthase uncoupling in aged mice
por: Shin, Woosung, et al.
Publicado: (2012)